Treatment of Residual, Non-infiltrating Bladder Cancer with Bacillus Calmette-guerin
- 1 May 1981
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 125 (5) , 649-651
- https://doi.org/10.1016/s0022-5347(17)55150-2
Abstract
Systemic and intracavitary administrations of BCG were used to treat patients with incompletely resected transitional cell carcinoma of the bladder. The treatment induced tumor regression in 59% of the patients. This trial confirms previous reports indicating that non-specific active immunotherapy is useful in the prevention of superficial recurrences and in the treatment of residual tumors that have not infiltrated.This publication has 9 references indexed in Scilit:
- Bacillus Calmette-guerin Immunotherapy of Superficial Bladder CancerJournal of Urology, 1980
- A Longitudinal Study of Patients with Superficial Bladder Carcinoma Successfully Treated with Weekly Intravesical Thio-TEPAJournal of Urology, 1979
- Partial Cystectomy in the Treatment of Transitional Cell Carcinoma of the BladderJournal of Urology, 1978
- Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancerUrology, 1977
- Intravesical Epodyl in the Management of Bladder Tumors: Combined Experience of the Yorkshire Urological Cancer Research GroupJournal of Urology, 1977
- Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder TumorsJournal of Urology, 1976
- Successful transurethral intralesional BCG therapy of a bladder melanomaCancer, 1975
- Benign Papilloma or Papillary Carcinoma of the Bladder?Journal of Urology, 1973
- EXTRACUTANEOUS DELAYED HYPERSENSITIVITY PARTICULARLY IN GUINEA-PIG BLADDER1966